Welcome to Scribd, the world's digital library. Read, publish, and share books and documents. See more
Standard view
Full view
of .
Look up keyword
Like this
0 of .
Results for:
No results containing your search query
P. 1
Traumeel S in Treatment of Chemotherapy-Induced Stoamatis 2001

Traumeel S in Treatment of Chemotherapy-Induced Stoamatis 2001

Ratings: (0)|Views: 18 |Likes:
Published by Dr. Nancy Malik
Uploaded from Google Docs
Uploaded from Google Docs

More info:

Published by: Dr. Nancy Malik on Jul 30, 2012
Copyright:Attribution Non-commercial


Read on Scribd mobile: iPhone, iPad and Android.
download as PDF, TXT or read online from Scribd
See more
See less





A Randomized, Controlled Clinical Trial of theHomeopathic Medication TRAUMEEL S
in theTreatment of Chemotherapy-Induced Stomatitis inChildren Undergoing Stem Cell Transplantation
Menachem Oberbaum,
Isaac Yaniv,
Yael Ben-Gal,
Jerry Stein,
Nurit Ben-Zvi,
Laurence S. Freedman,
David Branski,
The Institute of Research on ComplementaryMedicine, The Center of Integrated ComplementaryMedicine, Shaare Zedek Medical Center, Jerusa-lem, Israel.
Bone Marrow Transplantation Unit, The Schnei-der Children’s Medical Center of Israel, Rabin Med-ical Center, Petach Tikva, Sackler School of Med-icine, Tel-Aviv University, Israel.
Department of Mathematics, Statistics, andComputer Sciences, Bar-Ilan University. Ramat-Gan, Israel.
Department of Pediatrics, Shaare Zedek MedicalCenter, Hebrew University Medical School, Jerusa-lem, Israel.Supported by a grant from the International Societyof Homotoxicology, Baden-Baden, Germany.The authors are grateful to Dr. Yoram Neumannfrom the Department of Pediatric Hematology On-cology at The Chaim Sheba Medical Center (Tel- Aviv, Israel) for his help in the planning and designof the first version of the study protocol. They alsothank Nitzan Teva, R.N., for her initiative andenthusiastic work at the beginning of the study.Finally, the authors thank the nurses of the BoneMarrow Transplantation Unit at The SchneiderChildren’s Medical Center of Israel for their supportand patience during this study. Address for reprints: Menachem Oberbaum, M.D.,The Institute of Research on Complementary Med-icine, The Center of Integrated ComplementaryMedicine, Shaare Zedek Medical Center, P.O. Box3235, Jerusalem 91031, Israel; Fax:
972-2-6666975; E-mail: oberbaum@netvision.net.ilReceived December 21, 2000; revision receivedMarch 27, 2001; accepted April 9, 2001.
Stomatitis is a common consequence of chemotherapy and a con-dition for which there is little effective treatment. Although the management of patients with other chemotherapy-related toxicities has improved in recent years,the incidence of stomatitis is increasing because of more intensive treatment andis often a dose limiting factor in chemotherapy. The authors assessed the efficacy of a homeopathic remedy, TRAUMEEL S
, in the management of chemotherapy-induced stomatitis in children undergoing bone marrow transplantation.
A randomized, placebo-controlled, double-blind clinical trial was con-ducted in 32 patients ages 3–25 years who had undergone allogeneic (16 patients)or autologous (16 patients) stem cell transplantation. Of the 30 evaluable patients,15 were assigned placebo, and 15 were assigned TRAUMEEL S both as a mouthrinse, administered five times daily from 2 days after transplantation for a mini-mum of 14 days, or until at least 2 days after all signs of stomatitis were absent.Stomatitis scores were evaluated according to the World Health Organizationgrading system for mucositis.
A total of five patients (33%) in the TRAUMEEL S treatment group did notdevelop stomatitis compared with only one patient (7%) in the placebo group.Stomatitis worsened in only 7 patients (47%) in the TRAUMEEL S treatment groupcompared with 14 patients (93%) in the placebo group. The mean area under thecurve stomatitis scores were 10.4 in the TRAUMEEL S treatment group and 24.3 inthe placebo group. This difference was statistically significant (P
This study indicates that TRAUMEEL S may reduce significantly theseverity and duration of chemotherapy-induced stomatitis in children undergoing bone marrow transplantation.
© 2001 American Cancer Society.
, stomatitis, mucositis, autologous, allogeneic, stem celltransplantation, bone marrow transplantation, randomized, placebo-controlled, ho-meopathy, complementary medicine.
tomatitis occurs commonly as part of general inflammatory dam-age to the mucous membranes in patients receiving chemother-apy or radiation therapy to the oropharyngeal region. The overallincidence of reactive stomatitis is about 40%.
However, it is partic-ularly common in patients receiving 5-fluorouracil (5-FU) treat-ment
and is even more common in those undergoing radiationtherapy for malignancies of the head and neck, in which approxi-mately 80% of patients are affected.
In patients undergoing bonemarrow transplantation (BMT), the incidence of stomatitis reaches95%.
The mechanism of development of stomatitis is primarily cytotoxic,
© 2001 American Cancer Society
although neutropenia,
periodontal pathology,
poororal hygiene,
poor nutritional status,
and infectionsalso contribute to the condition. Morphologic character-istics can vary from slight erythema and edema of theoral mucosa to severe, focal, or widespread ulceration,bleeding and exudation.
In addition to pain and dis-comfort, loss of the mechanical barrier together with thelarge surface of necrotic mucosa and neutropenia canlead to secondary local infections, sepsis, and even life-threatening systemic infections.
Severe cases of stomatitis often necessitate the interruption of chemo-therapy treatment or dose reduction and may affect pa-tient compliance with further treatment.
Compared with other chemotherapy-related toxicities, such as my-elosuppression, the incidence of mucositis and the sig-nificance of its toxicity is increasing. Consequently, oralmucositis is becoming the most common dose-limiting toxicity of chemotherapy.
The current treatment of patients with stomatitisis essentially symptomatic. This includes stringentoral hygiene, avoiding irritating and abrasive foods,good oral and dental care, and the use of bland rinses,topical anesthetics, and systemic analgesics.
Suchtreatments, however, are of limited value and haveshown improvement only in patients with mild tomoderate stomatitis.
is a homeopathic-complex remedy that has been sold over the counter in pharmacies inGermany, Austria, and Switzerland for over 50 years. Itcontains extracts from the following plants and min-erals, all of them highly diluted (10
of the stemsolution): Arnica montana, Calendula officinalis, Achillea millefolium, Matricaria chamomilla, Symphy-tum officinale, Atropa belladonna, Aconitum napellus,Bellis perennis, Hypericum perforatum, chinacea an-gustifolia, Echinacea purpurea, Hamamelis virginica,Mercurius solubilis, and Hepar sulfuris. Informationfrom the manufacturer indicates that TRAUMEEL S isused normally to treat trauma, inflammation, and de-generative processes.Informal experience in patients with chemother-apy-related stomatitis suggests that the condition may respond to treatment with TRAUMEEL S homeopath-ic-complex remedy. Based on this and subsequentpositive results from a preliminary open study in 20patients with stomatitis who were treated withTRAUMEEL S compared with 7 untreated, randomly selected patients,
 we decided to conduct the ran-domized, placebo-controlled, double-blind clinicaltrial reported here.
Thirty-two consecutive patients who were admitted toSchneider Children’s Medical Center, ages 3–25 years,suffering from malignant diseases and underwentBMT were enrolled. Patients had undergone alloge-neic or autologous stem cell transplantation.
Thestudy was approved by the ethical committee at theRabin Medical Center, and informed, written consent was obtained from parents and/or guardians of allchildren prior to their enrolment in the study after afull explanation of the benefits, potential hazards, andprocedures involved in the study to the patients andtheir parents and/or guardians.
Study Medication
For this study, both TRAUMEEL S and placebo wereprovided by the HEEL Company (Baden-Baden, Ger-many) in sterile, 2.2-mL ampoules. Solutions of TRAUMEEL S were prepared by diluting the activesubstance in saline, according to the German Homeo-pathic Pharmacopoeia (HAB). The placebo consistedonly of saline. The active medication and placebo didnot differ in color, taste, or odor.TRAUMEEL S is manufactured according to theEuropean Union Guidelines on Good Manufacturing Practice for Medicinal Products
and in accordance with the HAB. The physical and microbiologic controlsof the medications were according to the EuropeanPharmacopoeia specifications.Extensive safety data from a large survey of TRAUMEEL S showed adverse events in only 0.0035%of patients, despite its use in over 3.5 million patients(manufacturer’s own survey). Adverse effects reported were mostly skin reactions to the cream or local pru-ritus as a reaction to injection. However, becauseTRAUMEEL S contains dilutions of substances thatmay be regarded as toxic, we calculated the content of one of the most toxic substances, a mercury salt, in themedication. Assuming that a patient will have to betreated with TRAUMEEL S for 1 week, he or she willreceive 35 ampoules. The mercury concentration of one ampoule is 0.5 ng/mL, giving a total amount of ingested mercury of approximately 17.5 ng per week.This compares favorably with the permitted mercury content of drinking water according to German law (0.001 mg/L).
Thus, a 1-week treatment oTRAUMEEL S contains approximately 10
of theamount of mercury deemed permissible in 1 L of drinking water.
Study Procedures
Thirty-two patients received various conditioning reg-imens for 5–8 days followed by autologous (16 pa-tients) or allogeneic (16 patients) stem cell infusion onDay 0. Patients were randomized to receive eitherplacebo or TRAUMEEL S on Day 2 of the study inaddition to twice-daily mouth washes with chlorohex-imide, oral amphoterin B, and gentle tooth brushing 
Treatment of Stomatitis/Oberbaum et al. 685
(institutional standard for mouth care). Packages of TRAUMEEL S and placebo were prepared by the HEELCompany and were identified by serial number only.The code showing the treatment corresponding toeach serial number was kept by the company, thestudy coordinator (M.O.), and the statistician (L.S.F.).The code was not broken until the completion of thetrial. Treatment was started on Day 2 after stem celltransplantation, so that treatment began before thefirst symptoms of stomatitis (e.g., dryness and/or sore-ness of the mouth) were observed. The peak incidenceof mucositis is typically 5–7 days after transplantation.Fifteen evaluable patients received placebo, and 15evaluable patients received TRAUMEEL S. Patients were instructed to rinse their mouths vigorously withthe solution for a minimum of 30 seconds beforeswallowing. In addition, patients were directed to keepthe liquid as long as possible on particularly trouble-some lesions in their mouth. This procedure was re-peated five times daily.The World Health Organization (WHO) grading system for mucositis (Table 1) was used to evaluatestomatitis in each patient.
In addition, a subjectivescoring system was used in which either the patient orthe parents were asked to judge the degree of oral painand discomfort, dryness of mouth and tongue, dys-phagia, and ability to swallow. A five-grade system wasused (Grade 0, no complaints; Grade 4, very severecomplaints, unable even to swallow liquids). The timeto worsening of stomatitis was evaluated as the timefrom randomization to the day when the mucositisscore increased from that recorded at baseline. Pa-tients were evaluated at least once every 2 days. Allevaluations were performed blind by the same ob-server (the study nurse). The trial continued until thepatient symptomology had been scored as Grade 0 on2 consecutive days or until a minimum of 14 days afterthe start of TRAUMEEL S or placebo treatment inpatients in whom no symptoms developed.The trial was carried out at the Bone Marrow Transplantation Unit, The Schneider Children’s Med-ical Center of Israel, Rabin Medical Center, PetachTikva, Israel. All study forms were collected, stored,and transferred to computer for analysis by the study coordinator (M.O.). Statistical analysis was performedat the Department of Mathematics, Statistics, andComputer Sciences, Bar-Ilan University, Ramat-Gan,Israel (L.S.F.). The randomization code was preparedby the manufacturer (HEEL Company) and was re-vealed only on completion of the study. Neither themanufacturer, the study coordinator, nor the statisti-cian was involved in any aspect of the treatment of participating patients.
Statistical Analysis
 All statistical analyses were done on an intent-to-treatbasis unless indicated otherwise. That is, each patient was considered to be allocated randomly to a groupregardless of the treatment actually received. The twomain treatment comparisons, as specified in the pro-tocol, were of the
area under the curve 
(AUC) forstomatitis symptoms, and the
time to first worsening 
of stomatitis symptoms. Both are based on the WHOgrading system.The AUC is equivalent to the sum of the grade oneach day from the start of TRAUMEEL S or placebotreatment. It therefore incorporates both severity andduration of symptoms. When grades were recordedevery other day, we used linear interpolation to esti-mate the stomatitis score on those days when evalu-ation did not occur. Because the AUC score distribu-tion was not normal, statistical comparison wasperformed using the two-sample Wilcoxon rank-sumtest.Most patients (77%) started TRAUMEEL S or pla-cebo treatment before the onset of symptoms. In thesepatients, therefore, the time to worsening of symp-toms was the same as the time to the start of symp-toms. Consequently, the time to worsening differedfrom time to first development of symptoms in only 23% of patients (17% with Grade 1 symptoms and 6% with Grade 2 symptoms). The statistical comparison of this endpoint was performed using the log-rank test. All
values reported are two-sided.
 A total of 32 patients were enrolled in this trial. How-ever, two patients (one in the TRAUMEEL S treatmentgroup and the other in the placebo group) received asingle dose of study drug but then refused furthertreatment, complaining of nausea. These patients were not evaluated subsequently for stomatitis and,thus, cannot be included in this analysis. Fifteen pa-tients each remained in the TRAUMEEL S group andthe placebo group. The distribution of patient charac-teristics for each group is shown in Table 2. Thegroups were comparable with regard to age, gender,type of BMT, granulocyte-colony stimulating factor
TABLE 1 World Health Organization Grading System for Mucositis
Grade Status
0 No change1 Soreness/erythema (painless)2 Erythema (painful), ulcers; can eat solids3 Ulcers; requires liquid diet onl4 Alimentation not possible
686 CANCER August 1, 2001 / Volume 92 / Number 3

You're Reading a Free Preview

/*********** DO NOT ALTER ANYTHING BELOW THIS LINE ! ************/ var s_code=s.t();if(s_code)document.write(s_code)//-->